Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug crawled time : 13:20 save search
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program
Published: 2023-08-21 (Crawled : 13:20) - biospace.com/
ENVB | $0.899 4.41% 4.23% 71K
|
Health Technology
|
| O: 6.05%
H: 3.07%
C: 1.32%
eb-373 drug preclinical program
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH
Published: 2023-08-15 (Crawled : 13:20) - globenewswire.com
IMUN | $0.093 214.52% 1.8K
|
Manufacturing
| Email alert
Add to watchlist
jkb-122 drug treatment
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
Published: 2023-07-20 (Crawled : 13:20) - globenewswire.com
SCYX | $1.53 6.25% 5.88% 150K
|
Health Technology
|
| O: -0.36%
H: 6.43%
C: 6.07%
pharma drug application china
Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in ChinaAcceptance of NDA Submission triggers as $2 million milestone payment to Ardelyx by Fosun Pharma
Published: 2023-07-13 (Crawled : 13:20) - biospace.com/
ARDX | $6.38 -2.0% -2.04% 3.8M
|
Health Technology
|
| O: 1.15%
H: 1.14%
C: -1.71%
pharma drug payment tenapanor hyperphosphatemia application milestone submission
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities
Published: 2023-07-07 (Crawled : 13:20) - biospace.com/
BRTX | $1.35 -2.17% -2.22% 89K
|
Professional, Scientific, and T...
|
| O: 0.49%
H: 1.93%
C: -7.71%
brtx-100 drug candidate test pipeline
ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
Published: 2023-05-24 (Crawled : 13:20) - globenewswire.com
CLPT | $5.505 -0.09% -0.09% 55K
|
Health Technology
|
| O: -1.46%
H: 2.59%
C: -2.35%
drug license agreement therapy
Azenta Announces Collaboration with the Lupus Research Alliance to Support the Advancement of Lupus Research and Drug Discovery
Published: 2023-05-24 (Crawled : 13:20) - biospace.com/
AZTA | $52.52 3.16% 3.07% 480K
|
n/a
|
| O: -0.97%
H: 0.0%
C: -3.02%
drug lupus research collaboration
BrainStorm Cell Therapeutics Summarizes Key Messages from Its Participation as Expert Speakers in an Invited Presentation and Panel Discussion at The 2023 ALS Drug Development Summit
Published: 2023-05-19 (Crawled : 13:20) - biospace.com/
BCLI A | $0.531 -1.69% -1.71% 170K
|
Health Technology
|
| O: 0.72%
H: 5.04%
C: 2.52%
drug als presentation cell therapeutics
US Senate Kicks Off Fresh Round of Drug Pricing Control Legislation
Published: 2023-04-26 (Crawled : 13:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
drug control
European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107
Published: 2023-04-26 (Crawled : 13:20) - biospace.com/
INO | $10.34 3.19% 3.09% 240K
|
Health Technology
|
| O: -0.18%
H: 2.4%
C: -1.56%
ino-3107 drug positive designation application
Accelerated Development and Manufacturing of Oral Small Molecules to be Discussed by Catalent Applied Drug Delivery Institute and JLABS
Published: 2023-03-30 (Crawled : 13:20) - catalent.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.18%
H: 0.14%
C: -0.1%
drug
Quantum-Si to Participate in B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation, Virtual Conference
Published: 2023-03-24 (Crawled : 13:20) - biospace.com/
QSI | $1.7 4.94% 4.71% 630K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 1.89%
C: 0.63%
drug conference life tools sciences
Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST
Published: 2023-03-23 (Crawled : 13:20) - biospace.com/
PCSA | $1.53 -2.27% 25K
|
Producer Manufacturing
|
| O: -3.58%
H: 6.5%
C: 5.28%
drug conference year update pharmaceuticals results
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome
Published: 2023-03-22 (Crawled : 13:20) - biospace.com/
MRNS | $1.455 -1.36% -1.37% 2.9M
|
Health Technology
|
| O: 0.0%
H: 2.4%
C: -3.85%
fda drug treatment pharmaceuticals designation
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders
Published: 2023-03-22 (Crawled : 13:20) - biospace.com/
GANX | $3.38 6.63% 6.21% 66K
|
Professional, Scientific, and T...
|
| O: -0.78%
H: 1.17%
C: -4.1%
drug computational therapeutics
Protai Adds $12 Million to Seed Round - Bringing the Total to $20 Million - to Build an Oncology Drug Discovery Pipeline
Published: 2023-03-15 (Crawled : 13:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
drug pipeline
Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.
Published: 2023-03-08 (Crawled : 13:20) - biospace.com/
LTRN | News | $5.8 1.4% 1.38% 130K
|
Health Technology
|
| O: -0.38%
H: 2.86%
C: -4.0%
pharma drug
Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis
Published: 2023-02-24 (Crawled : 13:20) - globenewswire.com
TMBR | $0.3426 -2.69% 3K
|
Health Technology
|
| O: 19.69%
H: 41.99%
C: 14.72%
tmb-001 pharmaceuticals designation drug
SeaStar Medical’s Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease Drug Development Summit
Published: 2023-02-24 (Crawled : 13:20) - globenewswire.com
ICU 4 | $0.486 11.52% 10.33% 2.1M
|
|
| O: -2.42%
H: 11.59%
C: 2.13%
drug device disease kidney
Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis
Published: 2023-02-21 (Crawled : 13:20) - biospace.com/
CMMB | $0.66 0.02% 0.02% 7.2K
|
Manufacturing
|
| O: 23.98%
H: 11.11%
C: -5.76%
cm-101 fda clearance drug application trial sclerosis
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.